Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 8 | 325 | 28% |
| 2020 | 8 | 317 | 30% |
| 2021 | 9 | 396 | 32% |
| 2022 | 10 | 441 | 35% |
| 2023 | 8 | 628 | 38% |
| 2024 | 12 | 677 | 39% |
| 2025 from claims | – | 714 577–838 | 40% |
| 2026 forecast | – | 796 624–1,000 | 39% |
| 2027 forecast | – | 876 650–1,158 | 40% |
| 2028 forecast | – | 964 683–1,331 | 40% |
| 2029 forecast | – | 1,061 721–1,521 | 40% |
| 2030 forecast | – | 1,167 765–1,732 | 40% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 95% of the cases CMS names in Massachusetts; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 2% inpatient hospital, 53% hospital outpatient, 46% office. The share outside the hospital has moved +46 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~800 | ~11 | ~370 | ~410 |
| 2027 · ~880 | ~11 | ~380 | ~480 |
| 2028 · ~960 | ~12 | ~410 | ~540 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 56% (46% in 2025), hospital outpatient about 42% (53% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,661+10%/yr | +10%/yr | 0.9 | 48% | 3,360 in 2030+12%/yr |
| Pennsylvania | 19 | 908−0.7%/yr | −0.7%/yr | 0.7 | 27% | 1,830 in 2030+12%/yr |
| New Jersey | 4 | 287+0.9%/yr | +0.9%/yr | 0.3 | 22% | 820 in 2030+19%/yr |
| Connecticut | 3 | 119−5.9%/yr | −5.9%/yr | 0.4 | 0% | 170 in 2030+6.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 117 | 7,183−0.3%/yr | −0.3%/yr | 8.00.9× | 12% | 8,190 in 2030+2.2%/yr |
| Tumor ablation | 4 | 431−1.7%/yr | −1.7%/yr | 0.51.8× | 0% | 590 in 2030+5.3%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Sirtex Medical leads with 25% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 19 companies reported engagement with Massachusetts’s surgeons worth $485K in consulting, speaking, meals and travel tied to these products, about $40K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.